FDA Approves Leucovorin for Cerebral Folate Deficiency in Some Autistic Individuals

The U.S. Food and Drug Administration (FDA) announced in September 2025 its approval of leucovorin calcium for treating cerebral folate deficiency (CFD) in autistic individuals. CFD is a metabolic condition characterized by low folate levels in the central nervous system despite normal blood folate levels, diagnosed through cerebrospinal fluid analysis or specialized antibody testing (Cureus review, 2025). This regulatory action targets a specific biological mechanism, not autism's core social communication or sensory processing differences.

A UCSD study published May 2026 analyzing 11.9 million medical records found leucovorin prescriptions for autistic children increased from approximately 500 monthly in 2023 to over 10,000 by early 2026—a 2000% rise following media coverage of small CFD studies. The Autism Research Institute notes that while leucovorin may help some individuals with confirmed CFD, there's no medication proven to address fundamental autistic traits, with current FDA-approved options like risperidone and aripiprazole only targeting co-occurring challenges like irritability (Frontiers, 2026).

As Yale researchers noted in 2026, biological heterogeneity means interventions helping some may not apply broadly.

Neurodiversity advocates stress the importance of distinguishing between treating metabolic conditions and altering autistic neurology. As Yale researchers noted in 2026, biological heterogeneity means interventions helping some may not apply broadly. Leucovorin's common side effects include nausea and sleep disturbances, with rare risks of allergic reactions (Medical Xpress, 2026).

Multiple clinical trials are exploring diverse approaches, from vasopressin nasal sprays to metabolic therapies (CORDIS, 2026), but the Stanford Autism Center emphasizes the need for personalized solutions that respect neurodivergent experiences rather than seeking universal 'treatments.'